Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (774)	12/11/2003 6:38:19 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

CNTO 95 Two short notes. - This appears to be a third and until now undisclosed Centocor mAb. Previously noted CNTO antibodies are: CNTO 148 - Centocor/J&J Anti-Inflammatory (Anti-TNFa) CNTO 1275 - Centocor/J&J Anti-Inflammatory (Anti-cytokine) - They didn't announce any milestone. Either there wasn't any or it was too tiny to even mention in a non-specific way in a PR message. Now they only have to announce the initiation of the colon cancer mAb before they can claim to have lived up to their mAbs-in-the-clinic-at year-end projection. Message 19343395 And we still have the AMGN antibody for which they claimed a milestone but where they were not quite clear on its clinical status. Maybe DD will clear that up at their information exercise today. Erik